<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00733993</url>
  </required_header>
  <id_info>
    <org_study_id>DA09262</org_study_id>
    <secondary_id>P50DA009262</secondary_id>
    <secondary_id>DPMCDA</secondary_id>
    <nct_id>NCT00733993</nct_id>
  </id_info>
  <brief_title>Caffeine and Cocaine</brief_title>
  <official_title>Experiment 1: Adenosine Receptor A2A Antagonists and Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to find out if medicines that affect a neurotransmitter (chemical
      messenger) in the brain called adenosine improve behavioral problems that are related to drug
      abuse. Another purpose of the study is to find out how genes related to adenosine change how
      people respond to these medicines. More information about how these medicines change
      behaviors may be helpful to come up with new treatments for drug abuse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific Aims:

      Aim 1. To characterize the behavioral and subjective effects of acute caffeine administration
      in cocaine-dependent subjects, using laboratory measures of impulse control, drug
      discrimination (with d-amphetamine as the training dose), and subjective effects.

      Hypotheses related to Aim 1:

        1. Subjects will show decreases in impulsivity (delay to reward and response inhibition)
           after acute oral doses of caffeine compared to placebo.

        2. Subjects will show some stimulant-like subjective effects following acute oral doses of
           caffeine, but not the euphoric effects that would predict abuse potential.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale Subjective Rating of Drug Effects</measure>
    <time_frame>Immediately after dose</time_frame>
    <description>Visual Analog Scale Rating. Scores range from 0 to 100 with higher scores meaning greater intensity of response being rated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic and Diastolic Blood Pressure</measure>
    <time_frame>Average across 7 time points: Immediately after dose and every 30 minutes for 3 hours</time_frame>
    <description>Sitting Blood Pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Average across 7 time points: Immediately after dose and every 30 minutes for 3 hours</time_frame>
    <description>Sitting heart rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Addiction Research Center Inventory Subjective Rating of Drug Effects</measure>
    <time_frame>Immediately after dose</time_frame>
    <description>Addiction Research Center Inventory (ARCI 49). T/F scales with 49 items.
Includes the following subscales:
Morphine-Benzedrine Group (MBG), includes euphoria (0 to +16, higher numbers = more euphoria) Phenobarbital-Chorpromazine-Alcohol Group (PCAG), includes sedation (-3 to +11, higher scores = more sedation) Lysergic Acid Diethylmide Group (LSD) , includes dysphoria and agitation (-4 to +10, higher scores = more dysphoria) Amphetamine Group (A), includes stimulation ( 0 to +11, higher scores = more stimulation) Benzedrine Group (BG), includes energy and &quot;intellectual efficiacy&quot; (+4 to +9, higher scores = more energy)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Effects Questionnaire Rating of Subjective Ratings of Drug Effects</measure>
    <time_frame>Immediately after dose</time_frame>
    <description>Assessments measured using a 4 item Drug Effects Questionnaire (DEQ) Ranges from 0 to 100 with higher numbers showing greater effect for each scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Probabalistic Feedback Selection Task</measure>
    <time_frame>75 minutes after dose</time_frame>
    <description>Accuracy on a range from 0 to 1 of correctly performing a learning task, with 1 being the highest degree of accuracy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saliva Caffeine and Paraxanthine Levels</measure>
    <time_frame>30 minutes prior to dose, 30/90/150 minutes post dose.</time_frame>
    <description>Due to insufficient oral volume or breakage during sample transfer, data were lost or incomplete for two cocaine-dependent subjects.
Analyses for the saliva data represent 11 cocaine-dependent subjects and 10 controls.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>1 Caffeine 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Caffeine 150 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Amphetamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amphetamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 Caffeine 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Caffeine 300 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine 150 MG</intervention_name>
    <description>Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion</description>
    <arm_group_label>1 Caffeine 150 mg</arm_group_label>
    <other_name>Vivarin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion</description>
    <arm_group_label>2 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amphetamine</intervention_name>
    <description>Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion</description>
    <arm_group_label>3 Amphetamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine 300 MG</intervention_name>
    <description>Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion</description>
    <arm_group_label>4 Caffeine 300 mg</arm_group_label>
    <other_name>Vivarin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who currently meet DSM-IV criteria for cocaine dependence and healthy
             controls

          -  At least one cocaine positive urine during screening.

          -  Current regular consumption of caffeine.

          -  Female subjects: a negative pregnancy test.

        Exclusion Criteria:

          -  Current or past DSM-IV Axis I disorder other than substance abuse/ dependence

          -  Any significant non-psychiatric medical illness requiring ongoing medical treatment or
             which would preclude treatment with d-amphetamine or caffeine

          -  Substance dependence other than cocaine within the last 3 months.

          -  Positive breath alcohol.

          -  Positive urine drug screen for drugs other than cocaine or THC at the time of
             behavioral testing

          -  For female subjects: known pregnancy or a positive pregnancy test or current breast
             feeding.

          -  Diagnosis of Adult Attention Deficit Disorder as determined by: a) meeting DSM-IV
             criteria for childhood ADHD, b) currently has impairing ADHD symptoms, c) ADHD
             symptoms can not have remitted at any period since childhood.

          -  HIV positive.

          -  I.Q. below 70.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick G Moeller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Health Science Center, Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lane SD, Green CE, Schmitz JM, Rathnayaka N, Fang WB, Ferr√© S, Moeller FG. Comparison of Caffeine and d-amphetamine in Cocaine-Dependent Subjects: Differential Outcomes on Subjective and Cardiovascular Effects, Reward Learning, and Salivary Paraxanthine. J Addict Res Ther. 2014;5(2):176.</citation>
    <PMID>25414797</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2008</study_first_submitted>
  <study_first_submitted_qc>August 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2008</study_first_posted>
  <results_first_submitted>July 14, 2016</results_first_submitted>
  <results_first_submitted_qc>February 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 22, 2017</results_first_posted>
  <last_update_submitted>February 1, 2017</last_update_submitted>
  <last_update_submitted_qc>February 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Virginia Commonwealth University</investigator_affiliation>
    <investigator_full_name>Frederick Gerard Moeller</investigator_full_name>
    <investigator_title>Professor - Division Chair, Addiction Psychiatry</investigator_title>
  </responsible_party>
  <keyword>substance abuse</keyword>
  <keyword>cocaine</keyword>
  <keyword>caffeine</keyword>
  <keyword>impulsivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Cocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cocaine Users</title>
          <description>Cocaine users were allocated to different sequence orders for the 5 interventions
Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion</description>
        </group>
        <group group_id="P2">
          <title>Control Participants</title>
          <description>Control participants were allocated to different sequence orders for the 5 interventions
Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cocaine Users</title>
          <description>Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion</description>
        </group>
        <group group_id="B2">
          <title>Control Participants</title>
          <description>Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Analog Scale Subjective Rating of Drug Effects</title>
        <description>Visual Analog Scale Rating. Scores range from 0 to 100 with higher scores meaning greater intensity of response being rated.</description>
        <time_frame>Immediately after dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo: Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion</description>
          </group>
          <group group_id="O2">
            <title>Caffeine 150 Mg</title>
            <description>150 MG of Caffeine</description>
          </group>
          <group group_id="O3">
            <title>Caffeine 300 mg</title>
            <description>Caffeine 300 mg</description>
          </group>
          <group group_id="O4">
            <title>Amphetamine 20 mg</title>
            <description>Amphetamine 20 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale Subjective Rating of Drug Effects</title>
          <description>Visual Analog Scale Rating. Scores range from 0 to 100 with higher scores meaning greater intensity of response being rated.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Elation: Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.65" spread="5.33"/>
                    <measurement group_id="O2" value="9.85" spread="5.32"/>
                    <measurement group_id="O3" value="13.65" spread="6.1"/>
                    <measurement group_id="O4" value="10.43" spread="4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elation: Cocaine (N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.99" spread="6.01"/>
                    <measurement group_id="O2" value="32.54" spread="7.62"/>
                    <measurement group_id="O3" value="21.65" spread="5.68"/>
                    <measurement group_id="O4" value="25.71" spread="6.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious: Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.15" spread="5.31"/>
                    <measurement group_id="O2" value="10.45" spread="5.69"/>
                    <measurement group_id="O3" value="8.50" spread="4.91"/>
                    <measurement group_id="O4" value="11.68" spread="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxious: Cocaine (N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.64" spread="6.17"/>
                    <measurement group_id="O2" value="21.35" spread="6.01"/>
                    <measurement group_id="O3" value="25.27" spread="7.12"/>
                    <measurement group_id="O4" value="21.71" spread="5.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vigor: Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.25" spread="2.06"/>
                    <measurement group_id="O2" value="8.50" spread="1.92"/>
                    <measurement group_id="O3" value="9.78" spread="1.98"/>
                    <measurement group_id="O4" value="8.28" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vigor: Cocaine (N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.42" spread="1.54"/>
                    <measurement group_id="O2" value="10.85" spread="1.59"/>
                    <measurement group_id="O3" value="9.27" spread="1.60"/>
                    <measurement group_id="O4" value="10.31" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tension: Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.38"/>
                    <measurement group_id="O2" value="1.60" spread="0.53"/>
                    <measurement group_id="O3" value="1.62" spread="0.60"/>
                    <measurement group_id="O4" value="1.53" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tension: Cocaine (N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.62"/>
                    <measurement group_id="O2" value="0.96" spread="0.57"/>
                    <measurement group_id="O3" value="2.38" spread="0.94"/>
                    <measurement group_id="O4" value="1.88" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.85" spread="1.37"/>
                    <measurement group_id="O2" value="3.00" spread="1.48"/>
                    <measurement group_id="O3" value="3.44" spread="1.64"/>
                    <measurement group_id="O4" value="3.60" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Cocaine (N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.32"/>
                    <measurement group_id="O2" value="0.54" spread="0.25"/>
                    <measurement group_id="O3" value="1.69" spread="0.71"/>
                    <measurement group_id="O4" value="1.17" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression: Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.10"/>
                    <measurement group_id="O2" value="0.10" spread="0.10"/>
                    <measurement group_id="O3" value="0.41" spread="0.30"/>
                    <measurement group_id="O4" value="0.10" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression: Cocaine (N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.54"/>
                    <measurement group_id="O2" value="0.62" spread="0.47"/>
                    <measurement group_id="O3" value="1.96" spread="1.12"/>
                    <measurement group_id="O4" value="1.10" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Systolic and Diastolic Blood Pressure</title>
        <description>Sitting Blood Pressure</description>
        <time_frame>Average across 7 time points: Immediately after dose and every 30 minutes for 3 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo: Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion</description>
          </group>
          <group group_id="O2">
            <title>Caffeine 150 Mg</title>
            <description>150 MG of Caffeine</description>
          </group>
          <group group_id="O3">
            <title>Caffeine 300 mg</title>
            <description>Caffeine 300mg</description>
          </group>
          <group group_id="O4">
            <title>Amphetamine 20mg</title>
            <description>Amphetamine 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic and Diastolic Blood Pressure</title>
          <description>Sitting Blood Pressure</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.64" spread="3.41"/>
                    <measurement group_id="O2" value="115.9" spread="4.07"/>
                    <measurement group_id="O3" value="117.36" spread="4.2"/>
                    <measurement group_id="O4" value="119.27" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP Cocaine (N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.18" spread="1.40"/>
                    <measurement group_id="O2" value="122.10" spread="1.81"/>
                    <measurement group_id="O3" value="123.84" spread="2.18"/>
                    <measurement group_id="O4" value="120.30" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.82" spread="2.78"/>
                    <measurement group_id="O2" value="75.33" spread="2.72"/>
                    <measurement group_id="O3" value="77.94" spread="1.42"/>
                    <measurement group_id="O4" value="77.83" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP Cocaine (N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.66" spread="3.01"/>
                    <measurement group_id="O2" value="79.98" spread="1.79"/>
                    <measurement group_id="O3" value="82.81" spread="1.74"/>
                    <measurement group_id="O4" value="78.16" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Heart Rate</title>
        <description>Sitting heart rate</description>
        <time_frame>Average across 7 time points: Immediately after dose and every 30 minutes for 3 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo: Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion</description>
          </group>
          <group group_id="O2">
            <title>Caffeine 150 Mg</title>
            <description>150 MG of Caffeine</description>
          </group>
          <group group_id="O3">
            <title>Caffeine 300 mg</title>
            <description>Caffeine 300mg</description>
          </group>
          <group group_id="O4">
            <title>Amphetamine 20mg</title>
            <description>Amphetamine 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <description>Sitting heart rate</description>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.10" spread="1.88"/>
                    <measurement group_id="O2" value="62.47" spread="2.09"/>
                    <measurement group_id="O3" value="61.33" spread="1.67"/>
                    <measurement group_id="O4" value="65.55" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cocaine (N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.08" spread="2.11"/>
                    <measurement group_id="O2" value="62.60" spread="3.00"/>
                    <measurement group_id="O3" value="61.57" spread="1.40"/>
                    <measurement group_id="O4" value="63.51" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Addiction Research Center Inventory Subjective Rating of Drug Effects</title>
        <description>Addiction Research Center Inventory (ARCI 49). T/F scales with 49 items.
Includes the following subscales:
Morphine-Benzedrine Group (MBG), includes euphoria (0 to +16, higher numbers = more euphoria) Phenobarbital-Chorpromazine-Alcohol Group (PCAG), includes sedation (-3 to +11, higher scores = more sedation) Lysergic Acid Diethylmide Group (LSD) , includes dysphoria and agitation (-4 to +10, higher scores = more dysphoria) Amphetamine Group (A), includes stimulation ( 0 to +11, higher scores = more stimulation) Benzedrine Group (BG), includes energy and &quot;intellectual efficiacy&quot; (+4 to +9, higher scores = more energy)</description>
        <time_frame>Immediately after dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo: Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion</description>
          </group>
          <group group_id="O2">
            <title>Caffeine 150 Mg</title>
            <description>150 MG of Caffeine</description>
          </group>
          <group group_id="O3">
            <title>Caffeine 300 mg</title>
            <description>Caffeine 300 mg</description>
          </group>
          <group group_id="O4">
            <title>Amphetamine 20 mg</title>
            <description>Amphetamine 20 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Addiction Research Center Inventory Subjective Rating of Drug Effects</title>
          <description>Addiction Research Center Inventory (ARCI 49). T/F scales with 49 items.
Includes the following subscales:
Morphine-Benzedrine Group (MBG), includes euphoria (0 to +16, higher numbers = more euphoria) Phenobarbital-Chorpromazine-Alcohol Group (PCAG), includes sedation (-3 to +11, higher scores = more sedation) Lysergic Acid Diethylmide Group (LSD) , includes dysphoria and agitation (-4 to +10, higher scores = more dysphoria) Amphetamine Group (A), includes stimulation ( 0 to +11, higher scores = more stimulation) Benzedrine Group (BG), includes energy and &quot;intellectual efficiacy&quot; (+4 to +9, higher scores = more energy)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCAG: Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.87" spread="0.82"/>
                    <measurement group_id="O2" value="3.62" spread="0.83"/>
                    <measurement group_id="O3" value="3.52" spread="0.79"/>
                    <measurement group_id="O4" value="3.64" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCAG: Cocaine (N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.95" spread="0.58"/>
                    <measurement group_id="O2" value="1.83" spread="0.68"/>
                    <measurement group_id="O3" value="2.95" spread="0.82"/>
                    <measurement group_id="O4" value="2.43" spread="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A: Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" spread="0.51"/>
                    <measurement group_id="O2" value="3.60" spread="0.68"/>
                    <measurement group_id="O3" value="3.80" spread="0.59"/>
                    <measurement group_id="O4" value="3.22" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A: Cocaine (N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="0.51"/>
                    <measurement group_id="O2" value="3.39" spread="0.54"/>
                    <measurement group_id="O3" value="3.19" spread="0.44"/>
                    <measurement group_id="O4" value="3.69" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BG: Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" spread="0.39"/>
                    <measurement group_id="O2" value="6.35" spread="0.56"/>
                    <measurement group_id="O3" value="6.05" spread="0.57"/>
                    <measurement group_id="O4" value="5.83" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BG: Cocaine (N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.69" spread="0.34"/>
                    <measurement group_id="O2" value="5.77" spread="0.37"/>
                    <measurement group_id="O3" value="5.07" spread="0.61"/>
                    <measurement group_id="O4" value="5.57" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MGB: Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.09" spread="1.26"/>
                    <measurement group_id="O2" value="4.34" spread="1.31"/>
                    <measurement group_id="O3" value="5.14" spread="1.37"/>
                    <measurement group_id="O4" value="4.04" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MGB: Cocaine (N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" spread="1.13"/>
                    <measurement group_id="O2" value="5.62" spread="1.23"/>
                    <measurement group_id="O3" value="4.31" spread="0.96"/>
                    <measurement group_id="O4" value="5.18" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LSD: Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="0.44"/>
                    <measurement group_id="O2" value="2.43" spread="0.56"/>
                    <measurement group_id="O3" value="1.23" spread="0.41"/>
                    <measurement group_id="O4" value="1.70" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LSD: Cocaine (N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.47"/>
                    <measurement group_id="O2" value="0.48" spread="0.49"/>
                    <measurement group_id="O3" value="1.05" spread="0.49"/>
                    <measurement group_id="O4" value="0.98" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Drug Effects Questionnaire Rating of Subjective Ratings of Drug Effects</title>
        <description>Assessments measured using a 4 item Drug Effects Questionnaire (DEQ) Ranges from 0 to 100 with higher numbers showing greater effect for each scale.</description>
        <time_frame>Immediately after dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo: Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion</description>
          </group>
          <group group_id="O2">
            <title>Caffeine 150 Mg</title>
            <description>150 MG of Caffeine</description>
          </group>
          <group group_id="O3">
            <title>Caffeine 300 mg</title>
            <description>Caffeine 300 mg</description>
          </group>
          <group group_id="O4">
            <title>Amphetamine 20 mg</title>
            <description>Amphetamine 20 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Effects Questionnaire Rating of Subjective Ratings of Drug Effects</title>
          <description>Assessments measured using a 4 item Drug Effects Questionnaire (DEQ) Ranges from 0 to 100 with higher numbers showing greater effect for each scale.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Feel effects:Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.75" spread="7.58"/>
                    <measurement group_id="O2" value="20.25" spread="6.31"/>
                    <measurement group_id="O3" value="9.45" spread="4.97"/>
                    <measurement group_id="O4" value="11.37" spread="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feel effects:Cocaine (N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.30" spread="5.80"/>
                    <measurement group_id="O2" value="20.73" spread="5.95"/>
                    <measurement group_id="O3" value="17.62" spread="5.91"/>
                    <measurement group_id="O4" value="18.68" spread="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Like effects:Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.92" spread="6.82"/>
                    <measurement group_id="O2" value="35.62" spread="6.89"/>
                    <measurement group_id="O3" value="52.17" spread="6.95"/>
                    <measurement group_id="O4" value="42.25" spread="5.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Like effects:Cocaine (N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.18" spread="9.74"/>
                    <measurement group_id="O2" value="39.94" spread="10.55"/>
                    <measurement group_id="O3" value="43.75" spread="7.21"/>
                    <measurement group_id="O4" value="32.04" spread="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High:Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.77" spread="5.23"/>
                    <measurement group_id="O2" value="12.17" spread="5.59"/>
                    <measurement group_id="O3" value="7.17" spread="4.16"/>
                    <measurement group_id="O4" value="7.17" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High:Cocaine (N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.35" spread="5.45"/>
                    <measurement group_id="O2" value="16.14" spread="5.67"/>
                    <measurement group_id="O3" value="15.87" spread="5.78"/>
                    <measurement group_id="O4" value="14.64" spread="5.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Like more:Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.77" spread="7.20"/>
                    <measurement group_id="O2" value="25.62" spread="6.54"/>
                    <measurement group_id="O3" value="32.92" spread="7.01"/>
                    <measurement group_id="O4" value="25.65" spread="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Like more:Cocaine (N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.96" spread="9.18"/>
                    <measurement group_id="O2" value="25.68" spread="8.99"/>
                    <measurement group_id="O3" value="28.71" spread="8.48"/>
                    <measurement group_id="O4" value="26.16" spread="8.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Probabalistic Feedback Selection Task</title>
        <description>Accuracy on a range from 0 to 1 of correctly performing a learning task, with 1 being the highest degree of accuracy.</description>
        <time_frame>75 minutes after dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo: Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion</description>
          </group>
          <group group_id="O2">
            <title>Caffeine 150 Mg</title>
            <description>150 MG of Caffeine</description>
          </group>
          <group group_id="O3">
            <title>Caffeine 300 mg</title>
            <description>Caffeine 300mg</description>
          </group>
          <group group_id="O4">
            <title>Amphetamine 20mg</title>
            <description>Amphetamine 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Probabalistic Feedback Selection Task</title>
          <description>Accuracy on a range from 0 to 1 of correctly performing a learning task, with 1 being the highest degree of accuracy.</description>
          <units>accuracy</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.02"/>
                    <measurement group_id="O2" value="0.55" spread="0.03"/>
                    <measurement group_id="O3" value="0.56" spread="0.02"/>
                    <measurement group_id="O4" value="0.61" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cocaine (N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.01"/>
                    <measurement group_id="O2" value="0.56" spread="0.02"/>
                    <measurement group_id="O3" value="0.58" spread="0.02"/>
                    <measurement group_id="O4" value="0.56" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saliva Caffeine and Paraxanthine Levels</title>
        <description>Due to insufficient oral volume or breakage during sample transfer, data were lost or incomplete for two cocaine-dependent subjects.
Analyses for the saliva data represent 11 cocaine-dependent subjects and 10 controls.</description>
        <time_frame>30 minutes prior to dose, 30/90/150 minutes post dose.</time_frame>
        <population>Assessment was not performed for amphetamine intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo
Placebo: Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion</description>
          </group>
          <group group_id="O2">
            <title>Caffeine 150 Mg</title>
            <description>150 MG of Caffeine</description>
          </group>
          <group group_id="O3">
            <title>Caffeine 300 mg</title>
            <description>Caffeine 300mg</description>
          </group>
          <group group_id="O4">
            <title>Amphetamine 20mg</title>
            <description>Amphetamine 20mg</description>
          </group>
        </group_list>
        <measure>
          <title>Saliva Caffeine and Paraxanthine Levels</title>
          <description>Due to insufficient oral volume or breakage during sample transfer, data were lost or incomplete for two cocaine-dependent subjects.
Analyses for the saliva data represent 11 cocaine-dependent subjects and 10 controls.</description>
          <population>Assessment was not performed for amphetamine intervention</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Caffeine -30 min Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1000" spread="490"/>
                    <measurement group_id="O2" value="510" spread="470"/>
                    <measurement group_id="O3" value="335" spread="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caffeine 30 min Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="983" spread="440"/>
                    <measurement group_id="O2" value="2715" spread="1110"/>
                    <measurement group_id="O3" value="2895" spread="998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caffeine 90 min Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="984" spread="445"/>
                    <measurement group_id="O2" value="2225" spread="995"/>
                    <measurement group_id="O3" value="3510" spread="1001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caffeine 150 min Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="984" spread="601"/>
                    <measurement group_id="O2" value="1910" spread="898"/>
                    <measurement group_id="O3" value="3270" spread="901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caffeine -30 min Cocaine (N=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="990" spread="920"/>
                    <measurement group_id="O2" value="998" spread="820"/>
                    <measurement group_id="O3" value="1201" spread="997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caffeine 30 min Cocaine (N=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="780" spread="510"/>
                    <measurement group_id="O2" value="2125" spread="1001"/>
                    <measurement group_id="O3" value="3510" spread="1220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caffeine 90 min Cocaine (N=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="625" spread="410"/>
                    <measurement group_id="O2" value="2077" spread="874"/>
                    <measurement group_id="O3" value="3720" spread="911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caffeine 150 min Cocaine (N=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="510" spread="322"/>
                    <measurement group_id="O2" value="1909" spread="605"/>
                    <measurement group_id="O3" value="3205" spread="697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parathanxine -30 min Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="440" spread="155"/>
                    <measurement group_id="O2" value="274" spread="140"/>
                    <measurement group_id="O3" value="198" spread="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parathanxine 30 min Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410" spread="240"/>
                    <measurement group_id="O2" value="301" spread="238"/>
                    <measurement group_id="O3" value="202" spread="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parathanxine 90 min Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="411" spread="219"/>
                    <measurement group_id="O2" value="402" spread="155"/>
                    <measurement group_id="O3" value="397" spread="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parathanxine 150 min Control (N=10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410" spread="143"/>
                    <measurement group_id="O2" value="411" spread="145"/>
                    <measurement group_id="O3" value="462" spread="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parathanxine -30 min Cocaine (N=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334" spread="205"/>
                    <measurement group_id="O2" value="401" spread="197"/>
                    <measurement group_id="O3" value="408" spread="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parathanxine 30 min Cocaine (N=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320" spread="275"/>
                    <measurement group_id="O2" value="465" spread="185"/>
                    <measurement group_id="O3" value="656" spread="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parathanxine 90 min Cocaine (N=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321" spread="248"/>
                    <measurement group_id="O2" value="601" spread="233"/>
                    <measurement group_id="O3" value="985" spread="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Parathanxine 150 min Cocaine (N=11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="296" spread="252"/>
                    <measurement group_id="O2" value="605" spread="247"/>
                    <measurement group_id="O3" value="1014" spread="255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1 Caffeine</title>
          <description>Caffeine
Caffeine: Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion</description>
        </group>
        <group group_id="E2">
          <title>2 Placebo</title>
          <description>Placebo
Placebo: Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion</description>
        </group>
        <group group_id="E3">
          <title>3 Amphetamine</title>
          <description>Amphetamine: Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>F. Gerard Moeller</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>804-828-4134</phone>
      <email>fgmoeller@vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

